We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
-12.67%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$167M
AUM Growth
-$14.7M
(-8.1%)
Cap. Flow
+$17.1M
Cap. Flow
% of AUM
10.22%
Top 10 Holdings %
Top 10 Hldgs %
63.99%
Holding
56
New
13
Increased
16
Reduced
7
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$9.25M |
| 2 |
Prothena Corp
PRTA
|
+$6.53M |
| 3 |
Charles River Laboratories
CRL
|
+$6.01M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$5.93M |
| 5 |
Encompass Health
EHC
|
+$5.87M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$7.14M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$4.53M |
| 3 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
+$3.93M |
| 4 |
MeiraGTx Holdings
MGTX
|
+$3.84M |
| 5 |
Humana
HUM
|
+$3.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.99% |
| 2 | Financials | 1.14% |
| 3 | Industrials | 0.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Prothena Corp
PRTA
$458M
| $21.8M | 13.04% |
441,000
+117,700
| +36% | +$6.53M |
|
|
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $19.1M | 11.42% |
345,900
+95,220
| +38% | +$4.97M |
|
|
ALBO
3
DELISTED
Albireo Pharma Inc
ALBO
| $12M | 7.17% |
514,082
+69,062
| +16% | +$1.84M |
|
|
LKFT
4
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $11M | 6.61% |
200,300
+100,300
| +100% | +$5.23M |
|
5
Cue Biopharma
CUE
$135M
| $9.38M | 5.61% |
27,635
+5,795
| +27% | +$2.24M |
|
|
6
Encompass Health
EHC
$11.2B
| $7.97M | 4.77% |
153,589
+113,809
| +286% | +$5.87M |
|
|
7
Oscar Health
OSCR
$8.5B
| $7.26M | 4.35% |
925,000
+736,600
| +391% | +$9.25M |
|
|
CNVY
8
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
| $6.5M | 3.89% |
777,000
+38,988
| +5% | +$286K |
|
|
KZR
9
DELISTED
Kezar Life Sciences
KZR
| $6.02M | 3.6% |
36,000
-26,996
| -43% | -$3.05M |
|
|
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
| $5.9M | 3.53% |
362,909
-127,973
| -26% | -$1.87M |
|
|
11
Charles River Laboratories
CRL
$10.9B
| $5.83M | 3.49% |
+15,481
| New | +$6.01M |
|
|
KALV
12
DELISTED
KalVista Pharmaceuticals
KALV
| $5.42M | 3.24% |
409,620
+152,229
| +59% | +$2.42M |
|
|
13
Alnylam Pharmaceuticals
ALNY
$36.3B
| $5.41M | 3.24% |
+31,907
| New | +$5.93M |
|
14
Aldeyra Therapeutics
ALDX
$91.7M
| $4.62M | 2.77% |
1,155,300
+420,300
| +57% | +$3.21M |
|
|
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.18M | 2.5% |
45,000
-108,400
| -71% | -$7.14M |
|
16
Agilon Health
AGL
$1.64B
| $4.05M | 2.42% |
6,000
+1,620
| +37% | +$986K |
|
|
MORF
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.45M | 2.07% |
72,898
+2,898
| +4% | +$155K |
|
18
ProQR Therapeutics
PRQR
$243M
| $2.86M | 1.71% |
356,617
+74,361
| +26% | +$566K |
|
19
Rocket Pharmaceuticals
RCKT
$348M
| $2.81M | 1.68% |
+128,705
| New | +$3.51M |
|
|
20
CALL
Prothena Corp
PRTA
$458M
| $2.57M | 1.54% |
+52,100
| New | +$2.89M |
|
21
PUT
Progyny
PGNY
$2.44B
| $2.52M | 1.51% |
50,000
-5,000
| -9% | -$280K |
|
22
Shattuck Labs
STTK
$710M
| $2.21M | 1.33% |
260,243
+91,002
| +54% | +$1.25M |
|
23
Cognition Therapeutics
CGTX
$82.3M
| $1.91M | 1.14% |
+301,979
| New | +$2.94M |
|
|
PANA
24
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
| $1.9M | 1.14% |
195,855
+6,915
| +4% | +$67.6K |
|
25
Globus Medical
GMED
$10.4B
| $1.46M | 0.87% |
+20,188
| New | +$1.47M |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q4 2021 Portfolio in Review
As of Q4 2021, Prosight Management held 56 positions worth $167M, down 8.1% from $182M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Prosight Management deployed $17.1M of net new capital in Q4 2021, opening 13 new positions and adding to 16 existing holdings. Its largest new stake was Charles River Laboratories: 15,481 shares worth $5.83M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 91% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Arena Pharmaceuticals Inc, an estimated $7.14M trimmed.
- Prosight Management's largest Q4 2021 buy was Charles River Laboratories: 15,481 shares worth $5.83M.
- Prosight Management added most to Oscar Health in Q4 2021, an estimated $9.25M increase.
- Prosight Management's biggest Q4 2021 reduction was Arena Pharmaceuticals Inc, cutting an estimated $7.14M.
- Prosight Management fully exited Metacrine, Inc. Common Stock in Q4 2021, selling an estimated $3.93M.
- Prosight Management's ten largest holdings make up 64% of its $167M portfolio in Q4 2021.
- Prosight Management opened 13 new positions and closed 20 in Q4 2021.
- Prosight Management's portfolio value fell 8.1% quarter-over-quarter to $167M.
Based on Prosight Management's 13F filing for Q4 2021, filed 14 Feb 2022.